Baseline characteristics of the 73 patients who were included in this MRI substudy
| Baseline parameter | Value |
|---|---|
| Age (years), mean±SD | 40.5±10.5 |
| BASDAI (0–10 units), mean±SD | 6.5±1.4 |
| BASFI (0–10 units), mean±SD | 5.9±1.6 |
| BASMI (0–10 units), mean±SD | 4.1±1.7 |
| CRP (mg/dL), mean±SD | 2.9±2.3 |
| Disease duration (years), mean±SD | 10±8.4 |
| HLA B27+ (%) | 61 (83.6%) |
| Male (%) | 63 (86.3%) |
There was no difference in comparison with patients who were initially included in AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT)24 and with all patients who participated in European AS Infliximab Cohort.25 The normal range of CRP was <0.5 mg/dL.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; HLA, human leukocyte antigen.